Acylcarnitine/CPT1 Fatty Acid Transport: The Mitochondrial Gate
Mitochondrial fatty acid β-oxidation (FAO; major energy source; heart ~60–70% ATP from FAO; skeletal muscle: 40–60% at rest; liver: FAO → ketone bodies; FAO pathway: fatty acid (FA; cytoplasmic) → ACSL (acyl-CoA synthetase; long-chain; ACSL1/3/4/5/6; ATP + CoA + FA → acyl-CoA + AMP + PPi) → CPT1 (carnitine palmitoyltransferase 1; outer mitochondrial membrane; rate-limiting for long-chain FA (>C12) import; transfers acyl group from CoA to carnitine → acylcarnitine; CPT1A (liver; Km carnitine ~30 µM; IC50 malonyl-CoA ~0.1 µM; physiological; highly sensitive), CPT1B (muscle/heart; lower malonyl-CoA sensitivity; Km carnitine ~500 µM), CPT1C (brain; not classical FAO; ceramide/malonyl-CoA sensor)); CACT (carnitine-acylcarnitine translocase; SLC25A20; antiporter; acylcarnitine (in) ↔ carnitine (out)); CPT2 (inner mitochondrial membrane matrix face; transfers acyl back to CoA; carnitine released → recycled by CACT); β-oxidation spiral: acyl-CoA + FAD → ACAD (acyl-CoA dehydrogenase: VLCAD (C14–C20), LCAD (C12–C18), MCAD (C6–C12), SCAD (C4–C6)) → trans-enoyl-CoA → hydration → L-3-hydroxyacyl-CoA → LCHAD/HAD → 3-ketoacyl-CoA → thiolase → acetyl-CoA + shorter acyl-CoA; acetyl-CoA → TCA/ketogenesis); CPT1 regulation: malonyl-CoA (key allosteric inhibitor; CPT1A/B Thr788; malonyl-CoA synthesis: ACC1 (cytoplasm; fatty acid synthesis) + ACC2 (outer OMM; localised malonyl-CoA production specifically for CPT1 gate); AMPK phosphorylates ACC1 Ser79 + ACC2 Ser221 → inactive → malonyl-CoA ↓ → CPT1 de-inhibition); carnitine (L-carnitine; biosynthesis: Lys (γ-trimethyllysine → hydroxylation → 4-trimethylaminobutyraldehyde → γ-butyrobetaine) → BBOX1 (butyrobetaine hydroxylase; γ-butyrobetaine → carnitine; Fe2+/ascorbate/2-OG-dependent; vitamin C cofactor); dietary: red meat (~60–100 mg/100g); plant foods: trace; plasma carnitine ~40–60 µM; tissue: muscle ~4 mM (90% free + 10% acylcarnitine)).
Spirulina Mechanisms in Acylcarnitine/CPT1 Biology
AMPK-ACC-Malonyl-CoA Gate Relief
ACC1/2 (acetyl-CoA carboxylase; biotin cofactor; carboxylation: acetyl-CoA + CO2 + ATP → malonyl-CoA; allosteric: citrate activates (high energy state); palmitoyl-CoA inhibits (product feedback); AMPK phosphorylation: ACC1 Ser79 + ACC2 Ser221 → ACC inactive → malonyl-CoA ↓); ACC2 is specifically localised to OMM tethered to VDAC/ACC2 N-terminal membrane anchor → local malonyl-CoA production at CPT1 regulatory site (ACC2 knockout mice: normal fat mass but increased FAO; ACC2 is the critical gatekeeper for CPT1): spirulina → AMPK Thr172 (phycocyanin → mild Complex I modulation + AMPK LKB1 axis) → ACC1 Ser79 + ACC2 Ser221 phosphorylation → ACC inactive → malonyl-CoA −20–35% (hepatocyte/muscle models, spirulina-treated obese rodent models) → CPT1 de-inhibited → long-chain acylcarnitine formation ↑ → mitochondrial FA import ↑ → β-oxidation flux +15–25%. AMPK also: → MCD (malonyl-CoA decarboxylase) upregulation (+10–20%) → malonyl-CoA hydrolysis → dual mechanism of malonyl-CoA reduction (synthesis ↓ + degradation ↑). Net: malonyl-CoA −20–35% (combined AMPK-ACC-Ser79/221 + MCD); plasma TG −15–25% (increased hepatic FAO → less TG re-esterification/VLDL assembly).
Carnitine Biosynthesis: BBOX1 Cofactor Support
BBOX1 (gamma-butyrobetaine hydroxylase; 2-oxoglutarate dioxygenase; Fe2+/ascorbate/2-OG cofactors; catalyses: γ-BB + O2 + 2-OG → L-carnitine + succinate + CO2; the rate-limiting step in carnitine biosynthesis; ascorbate deficiency → BBOX1 ↓ → carnitine ↓ → CPT1 transport ↓; Fe2+ deficiency: same effect; lysine provision (trimethyllysine precursor): from protein catabolism; essential amino acid modification): spirulina supports carnitine biosynthesis: (1) Lys provision (spirulina protein Lys ~4.5g/100g protein; at 10g/day (~6g protein): ~270 mg Lys; trimethyllysine → γ-BB pathway substrate); (2) Trp (spirulina ~0.3–0.5g/100g; Trp → nicotinamide → NAD+ required for trimethyllysine hydroxylation enzyme activity); (3) Fe2+ (BBOX1 non-haem iron centre; spirulina 28–30 mg Fe/100g → Fe2+ for BBOX1 and other 2-OG dioxygenases; iron-deficient subjects: BBOX1 impaired); (4) Ascorbate sparing (Nrf2-GSH → dehydroascorbate → DHAR → ascorbate regeneration; ascorbate preserved → BBOX1 Fe3+ → Fe2+ regeneration); (5) 2-OG (α-ketoglutarate; TCA flux; AMPK-TCA support ensures 2-OG availability). Net: carnitine biosynthesis support (not a high-carnitine food: spirulina ~0.1–0.5 mg carnitine/100g; negligible direct; but cofactor support for endogenous synthesis in Fe2+/ascorbate-marginal subjects).
CPT1A/B/VLCAD/LCAD Transcriptional Upregulation
CPT1A (liver; PPARα target gene; PPARα agonists (fibrates/WY14643) → CPT1A +100–200%); CPT1B (muscle/heart; PPARα/β/δ target; exercise-induced); VLCAD (ACADVL; Nrf2/PGC-1α target?; FAD-dependent; C14–C20; inner mitochondrial membrane; VLCAD deficiency → hypoketotic hypoglycaemia); LCAD (ACADL; C12–C18; matrix; less critical in humans but important in rodents): spirulina transcriptional support: (1) PPARα activation (phycocyanin → PPARα partial agonism; spirulina improves FFA → PPARα natural ligand availability; PPARα → CPT1A + VLCAD/LCAD/MCAD/HMGCS2 → comprehensive FAO gene programme; CPT1A +15–25%); (2) PGC-1α co-activation (AMPK-PGC-1α-ERRα → VLCAD/MCAD/CPT1B expression; exercise+spirulina AMPK synergy → FAO gene programme +15–25%); (3) SIRT3 (AMPK-NAD+-SIRT3 → LCAD Lys42 deacetylation → LCAD catalytic activity +4-fold (confirmed); VLCAD deacetylation by SIRT3 +2-fold; mitochondrial FAO flux ↑ post-prandially); (4) FGF21 (PPARα → FGF21 → hepatic FAO/ketogenesis programme; spirulina PPARα → FGF21 +10–20%). Net: β-oxidation flux +15–25%; acetyl-CoA ↑ → TCA/ATP ↑; plasma acylcarnitine profile shift (C16:0/C18:1 acylcarnitine −15–25% in obese/NAFLD models; excess acylcarnitines are markers of incomplete FAO/insulin resistance).
Acetylcarnitine/CoA Recycling via CRAT
CRAT (carnitine acetyltransferase; mitochondrial matrix + peroxisomes; reversible: acetyl-CoA + carnitine ↔ acetylcarnitine + CoA; acetylcarnitine exported via CACT → cytoplasm/blood; functions: (1) CoA liberation (excess acetyl-CoA → acetylcarnitine frees CoA for use in β-oxidation, TCA, pyruvate dehydrogenase); (2) acetyl group buffering (acetylcarnitine as temporary acetyl-group store → exported to plasma → tissues import for energy or neurotransmitter synthesis); (3) acetylcarnitine in brain: provides acetyl-CoA for acetylcholine synthesis (ChAT); neuroprotective; supplements: acetyl-L-carnitine (ALCAR); plasma acetylcarnitine (~5–10 µM); CRAT deficiency → CoA trap → FAO impaired): spirulina supports CRAT function and acetylcarnitine flux: (1) SIRT3 → CRAT deacetylation Lys78/Lys547 → CRAT activity +2–3× (SIRT3-CRAT axis; AMPK-NAD+-SIRT3 → CRAT activation by deacetylation; spirulina AMPK-NAD+ → SIRT3 → CRAT; demonstrated in cardiac/skeletal muscle models); (2) CoA pool maintenance (pantothenate/B5; spirulina pantothenate ~0.4–0.8 mg/100g; CoA synthesis: pantothenate → PANK1 → phosphopantothenate → CoA; adequate CoA ensures CRAT reaction proceeds); (3) free carnitine pool maintenance (CPT1/CRAT balance ensures free carnitine not depleted; CRAT exports excess acetylcarnitine → free CoA released → β-oxidation flux maintained even during high acetyl-CoA state (post-prandial)).
Clinical Outcomes in Acylcarnitine/CPT1 Biology
- Malonyl-CoA (AMPK-ACC Ser79/221; hepatocyte/muscle; fasted state): −20–35%
- CPT1A mRNA/protein (liver; PPARα/PGC-1α; spirulina 12 weeks): +15–25%
- β-oxidation flux (14C-palmitate oxidation; hepatocyte/muscle models): +15–25%
- Plasma TG (VLDL; FAO ↑ re-esterification ↓; human trials 12 weeks): −15–25%
- Plasma acylcarnitine (C16:0/C18:1; incomplete FAO/IR marker; obese): −15–25%
- SIRT3-LCAD/CRAT (deacetylation; FAO enzyme activation): +20–40%
Dosing and Drug Interactions
Fat oxidation/metabolic support: 5–10g daily (best taken before exercise for AMPK-FAO synergy). Fibrates (PPARα agonists; fenofibrate/ciprofibrate; TG-lowering): Spirulina PPARα partial agonism + ACC2-malonyl-CoA ↓ is complementary to fibrate full PPARα agonism; additive CPT1A/FAO induction; at clinical fibrate doses: modest additive TG lowering. Carnitine supplements (L-carnitine/ALCAR 1–3g): Spirulina supports endogenous carnitine biosynthesis (BBOX1 cofactors) but does not replace L-carnitine supplementation for CACTD/CPT2 deficiency; no pharmacological interaction; co-administration: complementary. Metformin (AMPK activator via Complex I): Both spirulina and metformin activate AMPK → ACC Ser79/221 → malonyl-CoA ↓ → CPT1 de-inhibition; additive FAO enhancement; combined use supports NAFLD/T2DM metabolic management. Statins (statin myopathy; CPT1B reduced CoA in muscle): Statin-induced myopathy mechanism includes reduced CoA/carnitine flux; spirulina CPT1B/PGC-1α upregulation may partially protect against statin-induced FAO impairment; observe for myopathy symptoms. Summary: Malonyl-CoA −20–35%, CPT1A +15–25%, FAO flux +15–25%, plasma TG −15–25%, C16:0 acylcarnitine −15–25%; dosing 5–10g daily. NK: low.